GSK, Crucell To Test Second-Generation Malaria Vaccine
GlaxoSmithKline and drug company Crucell, a division of Johnson & Johnson, will collaborate with the PATH Malaria Vaccine Initiative to test a second-generation malaria vaccine "within the next couple of months," Reuters reports. "GSK's first-generation vaccine, known as RTS,S or Mosquirix, is in late-stage development and could reach the market in 2015. ... The new vaccine is an amended version of the current GSK shot that adds an engineered common cold virus developed by Crucell to 'prime' the immune system to get a stronger response," the news service writes (Hirschler, 6/6).This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.